A Two Part Clinical Trial Assessing the Safety, Tolerability, Immunogenicity and Protective Efficacy of NMRC-M3V-Ad-PfCA, a Multivalent, Adenovirus-Vectored Plasmodium Falciparum Malaria Vaccine, in Healthy, Malaria-Naive Adults.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Malaria vaccine (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions; Therapeutic Use
- 11 Oct 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 12 Oct 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 18 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.